Floatz logo

RIFALDAZINE

Diffuse Large B-Cell Lymphoma (DLBCL)

Epizyme, Inc.Small moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

271 Active assets in the Diffuse Large B-Cell Lymphoma (DLBCL) cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
FILGRASTIM
Ruijin Hospital
Phase 3BBB
Inno-206
Beth Israel Deaconess Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

RIFALDAZINE is also rated in:

methicillin-resistant staphylococcus aureus infectious diseaseDormant
BB
Indicative ·
71 / 100
View asset →
cystic fibrosisDormant
BB
Indicative ·
65 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →